Recent studies highlight the clinical importance of NFE2L2-mutated urothelial carcinoma. This rare subset of bladder cancer demonstrates unique histological and molecular patterns. Historically, researchers linked NFE2L2 alterations to thoracic cancers. However, current data suggests these mutations also drive aggressive behavior in the urinary tract.

Histological Features of NFE2L2-Mutated Urothelial Carcinoma

Researchers observed that NFE2L2-mutated tumors frequently show concomitant squamous and myxoid features. Furthermore, these tumors exhibit significantly high PD-L1 expression. In many cases, nearly 90% of tumor cells demonstrate strong membranous staining. This high expression suggests a potential response to immune checkpoint inhibitors. Additionally, next-generation sequencing often reveals co-mutations in the TERT promoter and CDKN2A genes.

Clinical Prognosis and Therapeutic Options

Clinically, patients with this mutation often face a poor prognosis. Most patients present with or develop metastatic disease quickly. Consequently, the median overall survival is typically around 12 months. Therefore, early recognition of these specific features is vital for treatment planning. Clinicians may consider targeted therapies against the NRF2 signaling pathway or aggressive immunotherapy. Furthermore, further investigations with larger cohorts remain necessary to refine these diagnostic strategies.

Frequently Asked Questions

What is the role of NFE2L2 in urothelial carcinoma?

NFE2L2 encodes the NRF2 transcription factor. This factor regulates oxidative stress responses and metabolic homeostasis. Mutations in this gene lead to aggressive tumor behavior and resistance to conventional therapies.

How does PD-L1 expression affect treatment for these patients?

NFE2L2-mutated tumors often show high PD-L1 expression. This finding suggests that immunotherapy could be an effective treatment option, though clinical outcomes currently remain challenging.

Disclaimer: This content is for informational and educational purposes only and does not constitute professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

Wuori D et al. NFE2L2-mutated urothelial carcinomas frequently show concomitant myxoid and squamous features and have high PD-L1 expression. Histopathology. 2026 Jun 06. doi: 10.1111/his.70189. PMID: 42249733.

Wang J et al. Pan-cancer analysis of NFE2L2 mutations identifies a subset of lung cancers with distinct genomic and improved immunotherapy outcomes. Cancer Cell Int. 2023;23:229.

Akin DF et al. Dysregulation of the NRF2/KEAP1 signaling pathway and its impact on the development of bladder cancer. Exp Biomed Res. 2026;9(2).